Biotechnology
Xinhua Silk Road: Bailong Chuangyuan to showcase star products at SupplySide Global 2026 in Las Vegas
BEIJING, Oct. 20, 2026 /PRNewswire/ -- At the SupplySide Global to be held during October 28-30 in Las Vegas, U.S., Chinese functional ingredient producer Shandong Bailong Chuangyuan Bio-tech Co., Ltd. will exhibit and present a series of its star and innovative products. The company, an industr...
2026-10-20 17:26
2837
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD
A Collaboration Leads to Molecularbiological Innovation MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAM...
2026-10-20 14:10
1626
Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication
Advancing Commercialization Preparations to Expand Injectables Presence in China HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today a...
2026-10-20 09:00
2551
WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year
SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year. Frost & S...
2026-10-20 08:00
3337
Versiti becomes 10th U.S. blood center to adopt FDA-cleared automation from Terumo Blood and Cell Technologies
Automated whole blood processing will expand platelet production capacity and
help meet growing hospital demand
LAKEWOOD, Colo. and MILWAUKEE, Oct. 19, 2026 /PRNewswire/ -- Versiti has
become the 10th U.S. blood center to adopt the Reveos™ Automated Blood
Processing System
2026-10-19 22:00
4775
Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion Ba...
2026-10-19 21:00
2906
Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer
SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this role, Ms. Ma will oversee the Company's financi...
2026-10-19 20:00
2382
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit TherapeuticsInc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built on Akeso's first-in-class immuno-oncology (IO) c...
2026-10-19 19:59
2410
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data onits Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally...
2026-10-19 10:00
4228
Tsingke Customer Quality Audit Highlights Manufacturing Systems and Quality Controls
BEIJING, Oct. 14, 2026 /PRNewswire/ -- As synthetic biology expands into new applications, standardized manufacturing processes, reliable production data, and robust quality management systems are becoming increasingly important. Tsingke recently hosted an on-site customer quality audit conducted...
2026-10-14 22:19
1653
Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study
AI-powered whole-slide analysis provides insights into treatment response beyond conventional HER2 classification SEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced findings from a study p...
2026-10-14 21:00
2613
Neurophet Honored with Two Awards at the BioSpectrum Asia Excellence Awards 2026
* Receives Awards for MedTech Innovation and AI-Driven Clinical Development; Only Korean Company Recognized in Two Categories * Recognized for its capabilities in AI-driven clinical support and ICL services, with plans to expand partnerships with global CROs SEOUL, South Korea, Oct. 14, 2026 /...
2026-10-14 21:00
2238
MIRACELL to Host Stem Cell Science Day 2026 in Los Angeles, Featuring International Clinical Insights in Regenerative Medicine
- Leading South Korean and U.S. medical experts to share clinical insights into regenerative medicine - Austrian clinical study on 47 ACL rupture patients treated with SMART M-CELL published in peer-reviewed journal LOS ANGELES, Oct. 14, 2026 /PRNewswire/ -- Miracell U.S. Inc., the U.S. subsidi...
2026-10-14 19:00
1800
Prof. Gang Shen Named Among World's Top 2% Scientists for Fourth Consecutive Year
SHANGHAI, Oct. 14, 2026 /PRNewswire/ -- Prof. Gang Shen of Taikang ByBo Dental has been named among theWorld's Top 2% Scientists for the fourth consecutive year, according to the ninth edition of the database jointly released by Stanford University and Elsevier. Prof. Shen has been recognised on...
2026-10-14 18:18
1371
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
* Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's annual pipeline output efficiency. * AI-Enabled Molecular ...
2026-10-13 21:00
4040
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis...
2026-10-13 19:00
2898
Lunit and Discovery Life Sciences Collaborate to Expand AI-Powered Tissue Analysis for Biopharma Research
Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development. SEOUL, South Korea, Oct. 12, 2026 /PRNe...
2026-10-12 21:00
2761
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
* New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis * Late-breaking analysis shows significantly higher rat...
2026-10-12 01:00
4235
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoa...
2026-10-10 12:41
3502
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
* SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX...
2026-10-09 08:00
4377
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59917
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
55153
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52974
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
22439
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17777